Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria
Conditions
Interventions
JNT-517 Tablet
JNT-517 Tablet
+1 more
Locations
24
United States
University of California Los Angeles (UCLA) School of Medicine
Los Angeles, California, United States
University of Florida (UF) Health Shands Hospital
Gainesville, Florida, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Start Date
October 20, 2025
Primary Completion Date
March 1, 2028
Completion Date
April 1, 2028
Last Updated
April 8, 2026
NCT06628128
NCT05579548
NCT06560736
NCT06332807
NCT06780332
NCT04348708
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions